Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Robin Carhart-Harris, PhD, MA
- Target Recruit Count
- 120
- Registration Number
- NCT06626139
- Locations
- πΊπΈ
UCSF Mission Bay, San Francisco, California, United States
Treatment of Persistent Post-concussive Symptoms With Psilocybin Assisted Therapy
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 40
- Registration Number
- NCT06615908
- Locations
- π¨π¦
University of Calgary, Calgary, Alberta, Canada
Psilocybin Mechanism of Action (MOA)
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 60
- Registration Number
- NCT06592833
- Locations
- πΊπΈ
Center for Psychedelic Therapy Research, New York, New York, United States
Optimizing Microdosing and Meditation
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- National University of Natural Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT06560658
- Locations
- πΊπΈ
National University of Natural Medicine, Portland, Oregon, United States
Effects of Psilocybin on Shared Experience
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Western University, Canada
- Target Recruit Count
- 30
- Registration Number
- NCT06529939
Investigation to Understand and Optimize Psilocybin
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Elaine Sandler
- Target Recruit Count
- 141
- Registration Number
- NCT06512194
- Locations
- πΊπΈ
Vail Health Behavioral Health, Edwards, Colorado, United States
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 30
- Registration Number
- NCT06506019
- Locations
- π¨π¦
Toronto Western Hospital - University Health Network, Toronto, Ontario, Canada
Psychedelic-assisted Group Program for First Responders
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Empower Research Inc
- Target Recruit Count
- 32
- Registration Number
- NCT06471959
- Locations
- π¨π¦
Centre for Neurology Studies, Surrey, British Columbia, Canada
Mechanistic Studies of Psilocybin in Headache Disorders
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT06464367
- Locations
- πΊπΈ
VA Connecticut Healthcare System, West Haven, Connecticut, United States
Psilocybin Therapy for Depression in Parkinson's Disease
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Joshua Woolley, MD, PhD
- Target Recruit Count
- 60
- Registration Number
- NCT06455293
- Locations
- πΊπΈ
University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.